BFEC
GALT icon

Benjamin F. Edwards & Company’s Galectin Therapeutics GALT Stock Holding History

Benjamin F. Edwards & Company’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$4K Hold
1,775
– – ﹤0.01% 1931
2024
Q1 		$4K Hold
1,775
– – ﹤0.01% 1908
2023
Q4 		$3K Sell
1,775
-3,766
-68% -$7.3K ﹤0.01% 1944
2023
Q3 		$11K Hold
5,541
– – ﹤0.01% 1368
2023
Q2 		$8K Sell
5,541
-3,595
-39% -$6.1K ﹤0.01% 1446
2023
Q1 		$19K Sell
9,136
-25,276
-73% -$40.8K ﹤0.01% 1276
2022
Q4 		$39K Buy
34,412
+15,157
+79% +$20.2K ﹤0.01% 1142
2022
Q3 		$31K Hold
19,255
– – ﹤0.01% 1164
2022
Q2 		$25K Sell
19,255
-8,581
-31% -$12.3K ﹤0.01% 1194
2022
Q1 		$45K Sell
27,836
-1,779
-6% -$3.44K ﹤0.01% 1055
2021
Q4 		$61K Buy
29,615
+6,015
+25% +$17.2K ﹤0.01% 997
2021
Q3 		$92K Sell
23,600
-11,093
-32% -$37.6K ﹤0.01% 872
2021
Q2 		$111K Buy
34,693
+23,993
+224% +$85.4K 0.01% 817
2021
Q1 		$23K Buy
10,700
+1,000
+10% +$2.24K ﹤0.01% 1167
2020
Q4 		$22K Hold
9,700
– – ﹤0.01% 1133
2020
Q3 		$26K Buy
9,700
+8,200
+547% +$23K ﹤0.01% 1054
2020
Q2 		$5K Hold
1,500
– – ﹤0.01% 1422
2020
Q1 		$3K Hold
1,500
– – ﹤0.01% 1532
2019
Q4 		$4K Hold
1,500
– – ﹤0.01% 1662
2019
Q3 		$6K Hold
1,500
– – ﹤0.01% 1527
2019
Q2 		$6K Hold
1,500
– – ﹤0.01% 1558
2019
Q1 		$8K Hold
1,500
– – ﹤0.01% 1373
2018
Q4 		$5K Buy
+1,500
New +$7.17K ﹤0.01% 1447

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Benjamin F. Edwards & Company's GALT Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Galectin Therapeutics (GALT) position steady in Q2 2024 at 1,775 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1931.

Benjamin F. Edwards & Company first reported a position in GALT in Q4 2018 and has held it in 23 quarters since. The position peaked at $111K in Q2 2021. 73 funds tracked by Wall St. Rank hold GALT as of Q2 2024.

  • Benjamin F. Edwards & Company held 1,775 shares of Galectin Therapeutics worth $4K as of Q2 2024.
  • Benjamin F. Edwards & Company left its Galectin Therapeutics share count unchanged in Q2 2024.
  • Galectin Therapeutics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1931 holding.
  • Benjamin F. Edwards & Company first reported a position in Galectin Therapeutics in Q4 2018 and has held it in 23 quarters since.
  • Benjamin F. Edwards & Company's Galectin Therapeutics position peaked at $111K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.